Psychedelic microdosing has exploded in popularity in recent years, with a noticeable uptick during the COVID-19 pandemic. Research is exploring the possible mental health effects of microdosing.
A November 2021 studyTrusted Source, by the University of British Columbia (UBC), observed that people who microdosed psychedelics, such as psilocybin and LSD, reported less anxiety, depression, and stress than non-microdosers.
The international study, published in the journal Scientific Reports and the largest-ever of its kind, looked at how different microdose patterns and behaviors affected the well-being of individuals outside the laboratory.
“Microdosers are engaging in the practice with therapeutic and wellness-oriented intentions,” said Joseph Rootman, MA, lead author of the study and doctoral researcher in clinical psychology at UBC Okanagan.
link
From the study: Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers:
Our results indicate health and wellness motives and perceived mental health benefits among microdosers, and highlight the need for further research into the mental health consequences of microdosing including studies with rigorous longitudinal designs.
American Buddhist Net 